NG004

Phase 1Small molecule

NNovaGo Therapeutics AG

NG004 is one of 2 small molecule programs targeting Acute Spinal Cord Injury (SCI). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Spinal Cord Injury (SCI)Recruiting

Acute Spinal Cord Injury (SCI)Phase 1

Recruiting

Competition

Competitive Landscape

1 competitor in Acute Spinal Cord Injury (SCI)

#DrugCompanyPhaseTrials

KP-100IT

KKringle Pharma, Inc.

Phase 3

1 2

NG004

NNovaGo Therapeutics AG

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Acute Spinal Cord Injury (SCI)

NCT06817577

Clinical

Trials by Indication[1]

Acute Spinal Cord Injury (SCI)1 trial

A First-in-human (FIH) Clinical Trial to Investigate the Human Monoclonal Antibody NG004, Administrated Intrathecally in Acute Spinal Cord Injury (SCI) Patients

Recruiting·NNovaGo Therapeutics AG·Phase 1·NCT06817577·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NG004. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NG004 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NG004. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NovaGo Therapeutics AG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNovaGo Therapeutics AG

NG004

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Acute Spinal Cord Injury (SCI)1 trial

References

Drug Info

Quick Facts

Related News